Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2014

Open Access 01-12-2014 | Research

Circulating survivin levels in healthy and asthmatic pregnancy

Authors: Andras Bikov, Renata Bocskei, Noemi Eszes, Aniko Bohacs, Gyorgy Losonczy, Janos Rigo, Ildiko Horvath, Lilla Tamasi

Published in: Reproductive Biology and Endocrinology | Issue 1/2014

Login to get access

Abstract

Background

Asthma is one of the most common conditions which complicate pregnancy. Pro- and anti-apoptotic mechanisms can be modulated by asthma accompanying pregnancy. Survivin, an anti-apoptotic protein has been implicated in the pathomechanism of asthma and also in the development of pathological pregnancies; however survivin has not been studied in pregnant asthmatics.

Methods

Twenty-eight asthmatic pregnant (AP), 25 asthmatic non-pregnant (ANP), 21 healthy pregnant (HP) and 29 healthy non-pregnant (HNP) women were enrolled in this cross-sectional study. Plasma survivin concentration was determined by ELISA.

Results

Plasma survivin was significantly lower in HP (1.64 /0-74.9/ pg/ml) than in HNP (24.6 /0-333.3/ pg/ml, p = 0.01). However, this difference was not observed between the asthmatic groups (p = 0.64). Similarly, there was no difference either between HNP and ANP (10.5 /0-215.4/ pg/ml, p = 0.23) or between HP and AP (13.9 /0-364.1/ pg/ml, p = 0.30) groups.

Conclusions

Decreased plasma survivin levels in physiological but not in asthmatic pregnancy may suggest that the normal apoptotic mechanisms are compromised in asthmatic gestation.
Appendix
Available only for authorised users
Literature
1.
Tamasi L, Somoskovi A, Muller V, Bartfai Z, Acs N, Puho E, Czeizel AE: A population-based case–control study on the effect of bronchial asthma during pregnancy for congenital abnormalities of the offspring. J Asthma. 2006, 43: 81-86. 10.1080/02770900500448803.CrossRefPubMed
2.
Dombrowski MP: Asthma and pregnancy. Obstet Gynecol. 2006, 108: 667-681. 10.1097/01.AOG.0000235059.84188.9c.CrossRefPubMed
3.
Maselli DJ, Adams SG, Peters JI, Levine SM: Management of asthma during pregnancy. Ther Adv Respir Dis. 2013, 7: 87-100. 10.1177/1753465812464287.CrossRefPubMed
4.
Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L: Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod. 2005, 11: 35-41.CrossRefPubMed
5.
Taylor DD, Sullivan SA, Eblen AC, Gercel-Taylor C: Modulation of T-cell CD3-zeta chain expression during normal pregnancy. J Reprod Immunol. 2002, 54: 15-31. 10.1016/S0165-0378(01)00067-5.CrossRefPubMed
6.
Redman CW, Sargent IL: Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta. 2008, 29 (A): S73-S77.CrossRefPubMed
7.
Bohacs A, Pallinger E, Tamasi L, Rigo J, Komlosi Z, Muller V, Dong Y, Magyar P, Falus A, Losonczy G: Surface markers of lymphocyte activation in pregnant asthmatics. Inflamm Res. 2010, 59: 63-70. 10.1007/s00011-009-0070-2.PubMedCentralCrossRefPubMed
8.
Tamasi L, Bohacs A, Tamasi V, Stenczer B, Prohaszka Z, Rigo J, Losonczy G, Molvarec A: Increased circulating heat shock protein 70 levels in pregnant asthmatics. Cell Stress Chaperones. 2010, 15: 295-300. 10.1007/s12192-009-0143-8.PubMedCentralCrossRefPubMed
9.
Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH, Chang JY: Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013, 6: 1453-1462.PubMedCentralCrossRefPubMed
10.
Shiozaki A, Kataoka K, Fujimura M, Yuki H, Sakai M, Saito S: Survivin inhibits apoptosis in cytotrophoblasts. Placenta. 2003, 24: 65-76. 10.1053/plac.2002.0860.CrossRefPubMed
11.
Muschol-Steinmetz C, Friemel A, Kreis NN, Reinhard J, Yuan J, Louwen F: Function of survivin in trophoblastic cells of the placenta. PLoS One. 2013, 8: e73337-10.1371/journal.pone.0073337.PubMedCentralCrossRefPubMed
12.
Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998, 351: 882-883. 10.1016/S0140-6736(05)70294-4.CrossRefPubMed
13.
Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, Ganapathy V, Chandler P, Choubey D, Abrams SI, Liu K: IFN-gamma upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. PLoS One. 2010, 5: e14076-10.1371/journal.pone.0014076.PubMedCentralCrossRefPubMed
14.
Lehner R, Bobak J, Kim NW, Shroyer AL, Shroyer KR: Localization of telomerase hTERT protein and survivin in placenta: relation to placental development and hydatidiform mole. Obstet Gynecol. 2001, 97: 965-970. 10.1016/S0029-7844(01)01131-0.CrossRefPubMed
15.
Li CF, Gou WL, Li XL, Wang SL, Yang T, Chen Q: Reduced expression of survivin, the inhibitor of apoptosis protein correlates with severity of preeclampsia. Placenta. 2012, 33: 47-51. 10.1016/j.placenta.2011.10.008.CrossRefPubMed
16.
Jutzy JM, Khan S, Asuncion-Valenzuela MM, Milford TA, Payne KJ, Wall NR: Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro. Cancer Microenviron. 2013, 6: 57-68. 10.1007/s12307-012-0096-9.PubMedCentralCrossRefPubMed
17.
Ungvari I, Hullam G, Antal P, Kiszel PS, Gezsi A, Hadadi E, Virag V, Hajos G, Millinghoffer A, Nagy A, Kiss A, Semsei AF, Temesi G, Melegh B, Kisfali P, Szell M, Bikov A, Galffy G, Tamasi L, Falus A, Szalai C: Evaluation of a partial genome screening of two asthma susceptibility regions using bayesian network based bayesian multilevel analysis of relevance. PLoS One. 2012, 7: e33573-10.1371/journal.pone.0033573.PubMedCentralCrossRefPubMed
18.
Tumes DJ, Connolly A, Dent LA: Expression of survivin in lung eosinophils is associated with pathology in a mouse model of allergic asthma. Int Immunol. 2009, 21: 633-644. 10.1093/intimm/dxp032.CrossRefPubMed
19.
Ungvari I, Hadadi E, Virag V, Bikov A, Nagy A, Semsei AF, Galffy G, Tamasi L, Horvath I, Szalai C: Implication of BIRC5 in asthma pathogenesis. Int Immunol. 2012, 24: 293-301. 10.1093/intimm/dxs007.CrossRefPubMed
20.
Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, Tomonaga M, Murata K, Sohda H, Nakagoe T, Shibasaki S, Yamada Y, Kamihira S: Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol. 2004, 80: 52-58. 10.1532/IJH97.04031.CrossRefPubMed
21.
Yang M, Liu Y, Lu S, Wang Z, Wang R, Zi Y, Li J: Analysis of the expression levels of survivin and VEGF in patients with acute lymphoblastic leukemia. Exp Ther Med. 2013, 5: 305-307.PubMedCentralPubMed
22.
El-Attar HA, Kandil MH, El-Kerm YM, El-Ghandour MK: Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev. 2010, 11: 897-903.PubMed
23.
Bokarewa M, Lindblad S, Bokarew D, Tarkowski A: Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R349-R358. 10.1186/ar1498.PubMedCentralCrossRefPubMed
24.
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005, 171: 912-930.
25.
Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB: Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004, 113: 59-65. 10.1016/j.jaci.2003.09.008.CrossRefPubMed
26.
Faul F, Erdfelder E, Buchner A, Lang AG: Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009, 41: 1149-1160. 10.3758/BRM.41.4.1149.CrossRefPubMed
27.
Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge WH, Wall NR: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer. 2009, 100: 1073-1086. 10.1038/sj.bjc.6604978.PubMedCentralCrossRefPubMed
28.
Toldi G, Molvarec A, Stenczer B, Muller V, Eszes N, Bohacs A, Bikov A, Rigo J, Vasarhelyi B, Losonczy G, Tamasi L: Peripheral T(h)1/T(h)2/T(h)17/regulatory T-cell balance in asthmatic pregnancy. Int Immunol. 2011, 23: 669-677. 10.1093/intimm/dxr074.CrossRefPubMed
29.
Molvarec A, Szarka A, Walentin S, Beko G, Karadi I, Prohaszka Z, Rigo J: Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia. Reprod Biol Endocrinol. 2011, 9: 124-10.1186/1477-7827-9-124.PubMedCentralCrossRefPubMed
30.
Bikov A, Bohacs A, Eszes N, Weiszhar Z, Ivancso I, Muller V, Rigo J, Losonczy G, Tamasi L, Horvath I: Circulating and exhaled vascular endothelial growth factor in asthmatic pregnancy. Biomarkers. 2012, 17: 648-654. 10.3109/1354750X.2012.713004.CrossRefPubMed
31.
Beierle EA, Nagaram A, Dai W, Iyengar M, Chen MK: VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res. 2005, 127: 21-28. 10.1016/j.jss.2005.03.009.CrossRefPubMed
32.
Formby B, Wiley TS: Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem. 1999, 202: 53-61. 10.1023/A:1007081021483.CrossRefPubMed
33.
Tamasi L, Bohacs A, Pallinger E, Falus A, Rigo J, Muller V, Komlosi Z, Magyar P, Losonczy G: Increased interferon-gamma- and interleukin-4-synthesizing subsets of circulating T lymphocytes in pregnant asthmatics. Clin Exp Allergy. 2005, 35: 1197-1203. 10.1111/j.1365-2222.2005.02322.x.CrossRefPubMed
34.
Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000, 2: 469-475. 10.1038/35019501.CrossRefPubMed
35.
Molvarec A, Tamasi L, Losonczy G, Madach K, Prohaszka Z, Rigo J: Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancies. Cell Stress Chaperones. 2010, 15: 237-247. 10.1007/s12192-009-0146-5.PubMedCentralCrossRefPubMed
Metadata
Title
Circulating survivin levels in healthy and asthmatic pregnancy
Authors
Andras Bikov
Renata Bocskei
Noemi Eszes
Aniko Bohacs
Gyorgy Losonczy
Janos Rigo
Ildiko Horvath
Lilla Tamasi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2014
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-12-93

Other articles of this Issue 1/2014

Reproductive Biology and Endocrinology 1/2014 Go to the issue

Review

Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis

Research

Use of antagonists and morpholinos in loss-of-function analyses: estrogen receptor ESR2a mediates the effects of 17alpha-ethinylestradiol on primordial germ cell distribution in zebrafish

Research

Early detection and staging of spontaneous embryo resorption by ultrasound biomicroscopy in murine pregnancy

Research

Characterizing semen parameters and their association with reactive oxygen species in infertile men

Review

Making gametes from pluripotent stem cells – a promising role for very small embryonic-like stem cells

Research

Delaying the oocyte maturation trigger by one day leads to a higher metaphase II oocyte yield in IVF/ICSI: a randomised controlled trial